– USA, MA – Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced the appointment of Dr. Darcy Mootz (Ph.D.) to its Board of Directors, bringing expertise across corporate strategy, corporate development, finance, and operations to the Board.
“We are pleased to welcome Darcy to the Elevation Oncology board, as she is a uniquely qualified leader, who has experience crafting late-stage development strategies, advancing products towards approval and launching new medicines for the treatment of cancer. IHer broad expertise complements the strengths and skills of Elevation Oncology’s Board of Directors, and I am confident she will provide important perspective as we continue to advance EO-3021 through clinical development. We look forward to Darcy’s many contributions,” said Board chairman, Steve Elms.
About Dr. Darcy Mootz
Dr. Darcy Mootz is an experienced life sciences executive who serves as President of Architect Therapeutics, a position she has held since April 2023. She previously served as Head of Amunix Pharmaceuticals from February 2022 until April 2023 and was CBO of Amunix from February 2019 to February 2022. Before joining Amunix, Dr. Mootz was an independent consultant working with venture capital firms and life sciences companies on corporate development and strategy projects. Before that, she served as CBO of ORIC Pharmaceuticals, and, earlier, served as P of Corporate Development at Achaogen. Dr. Mootz also serves on the Board of Directors of Alpha-9 Oncology.
“I am honored to join the Elevation Oncology board,” said Dr. Darcy Mootz. “Based on data presented by Elevation Oncology’s partner, I believe EO-3021 is a highly differentiated, potential best-in-class anti-Claudin 18.2 ADC with the potential to transform the care of patients with gastric cancer and other cancer types. I am excited to partner with the team to advance this program and build a pipeline of selective cancer therapies for a range of unmet medical needs.”
She received a B.S. in Biology from Duke University and a Ph.D. in Biochemistry from Harvard University.
About Elevation Oncology, Inc.
Elevation Oncology is an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. We are rethinking drug development by seeking out innovative, selective cancer therapies that can be matched to a patient’s unique tumor characteristics. Our lead candidate, EO-3021, is a potential best-in-class antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target. EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. We are evaluating EO-3021 in a Phase 1 study in patients with advanced, unresectable, or metastatic solid tumors likely to express Claudin 18.2 including gastric, gastroesophageal, pancreatic, or esophageal cancers. We are also exploring other opportunities through new or existing partnerships and business development opportunities to expand our oncology pipeline.
SOURCE: https://elevationoncology.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.